AzTrials
AzTrials

Solid TumorsPhase 2NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

A Phase 2 study testing Adagrasib, Pembrolizumab and Cetuximab in people with Solid Tumors, run by Mirati Therapeutics Inc. at 101 sites in 21 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumors
What is being tested?
Adagrasib, Pembrolizumab and Cetuximab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
170 participants
Where
101 sitesin 21 countries
Study dates
6 May 2026to 16 Feb 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
  • Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Who cannot join

  • Participant is not eligible for study treatment per the parent study eligibility criteria.
  • Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
  • Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
  • Other protocol defined inclusion/exclusion criteria applies.

Trial locations and contacts

101 sites in 21 countries. Contact the study team or a site near you to ask about taking part.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #. contact

101 sites in 21 countries

France18 sites, 17 recruiting

  • ICO Papin

    Angers, Maine-et-Loire, 49055

    Frederic Bigot, Site 0032, 33241352700

    Recruiting

  • Chu Jean Minjoz

    Besançon, Doubs, 25000

    Elodie Klajer, Site 0091, 33381479999

    Recruiting

  • Hospices Civils de Lyon - Hopital Louis Pradel

    Bron, Rhône, 69677

    Michael Duruisseaux, Site 0090, 33427857700

    Recruiting

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94010

    Gaelle Rousseau-Bussac, Site 0085, 33157022102

    Recruiting

  • L Hopital Nord Ouest

    Gleizé, Rhône, 69400

    LIONEL FALCHERO, Site 0075, +33642346915

    Recruiting

  • Chu Grenoble Alpes

    La Tronche, Isère, 38700

    Denis Moro-Sibilot, Site 0065, 33476765467

    Recruiting

  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord

    Marseille, 13915

    PASCALE TOMASINI, Site 0059, +33491965901

    Recruiting

  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur

    Nice, Alpes-Maritimes, 06000

    Jacques Boutros, Site 0076, 0492037767

    Recruiting

  • Centre Antoine-Lacassagne

    Nice, Alpes-Maritimes, 06189

    Victoria ferrari, Site 0086, 0492031324

    Recruiting

  • Groupe hospitalier Paris saint Joseph

    Paris, Île-de-France Region, 75014

    Charles Naltet, Site 0061, 33144123752

    Recruiting

  • CHU Bordeaux Haut-Leveque

    Pessac, Aquitaine, 33600

    Remi Veillon, Site 0103, 33557656338

    Recruiting

  • Local Institution - 0051

    Poitiers, Vienne, 86021

    Withdrawn

  • Centre Hospitalier de Cornouaille Quimper - Concarneau

    Quimper, 29000

    Romain Corre, Site 0058, 33899282481

    Recruiting

  • Local Institution - 0063

    Saint-Herblain, Loire-Atlantique, 44800

    Site 0063

    Not yet recruiting

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, Loire-Atlantique, 44805

    Sandrine Hiret, Site 0050, 33240679978

    Recruiting

  • Hôpital d'Instruction des Armées Bégin

    Saint-Mandé, 94160

    Hugo PICCHI, Site 0078, +33631841829

    Recruiting

  • Nouvel Hôpital Civil (NHC)

    Strasbourg, Alsace, 67091

    Celine Mascaux, Site 0074, 0033369550644

    Recruiting

  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau

    Tours, 37032

    Thierry Lecomte, Site 0077, 33218370522

    Recruiting

Other trials in France

United States17 sites, 13 recruiting

  • Texas Oncology-Bedford

    Bedford, Texas, 76022

    Kartik Konduri, Site 0117, 214-370-1000

    Recruiting

  • Southern California Permanente Medical Group

    Bellflower, California, 90706

    Gary Buchschacher, Site 0016, 000-000-0000

    Recruiting

  • PeaceHealth St. Joseph Medical Center

    Bellingham, Washington, 98225

    Navdeep Sangha, Site 0013, 323-783-5752

    Recruiting

  • Local Institution - 0092

    Boston, Massachusetts, 00215

    Withdrawn

  • Local Institution - 0080

    Boston, Massachusetts, 02215

    Active, not recruiting

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas, 75246

    Kartik Konduri, Site 0118, 214-370-1000

    Recruiting

  • Oncology Associates Of Oregon, Pc

    Eugene, Oregon, 97401

    Jeff Porter Sharman, Site 0004, 888-542-2525

    Recruiting

  • The West Clinic, PLLC dba West Cancer Center

    Germantown, Tennessee, 38138

    Ramakrishna Battini, Site 0023, 901-683-0055

    Recruiting

  • Texas Oncology - DFW

    Grapevine, Texas, 76051

    Kartik Konduri, Site 0002, 214-370-1000

    Recruiting

  • MemorialCare - Long Beach Medical Center

    Long Beach, California, 90806

    Nilesh Vora, Site 0082, 562-997-4070

    Recruiting

  • Local Institution - 0003

    Newark, Delaware, 19713

    Withdrawn

  • Nebraska Cancer Specialists

    Omaha, Nebraska, 68114

    Mary Wells, Site 0036, 531-329-3667

    Recruiting

  • Local Institution - 0005

    Phoenix, Arizona, 85054

    Withdrawn

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota, 55905

    Konstantinos Leventakos, Site 0017, 507-284-2511

    Recruiting

  • Metro-Minnesota Community Oncology Research Consortium (MMCORC)

    Saint Paul, Minnesota, 55101

    Yan Ji, Site 0073

    Recruiting

  • Florida Cancer Specialists - North

    St. Petersburg, Florida, 33701

    Maen Hussein, Site 0001, 727-216-1143

    Recruiting

  • Cancer Center of Kansas

    Wichita, Kansas, 67208

    Shaker Dakhil, Site 0112, 316-262-4467

    Recruiting

Other trials in United States

Spain14 sites, 14 recruiting

  • CHUAC-Complejo Hospitalario Universitario A Coruña

    A Coruña, A Coruña [La Coruña], 15006

    Maria Garcia Campelo, Site 0007, 34981178353

    Recruiting

  • Institut Catala d'Oncologia-Hospital Germans Trias i Pujol

    Badalona, Barcelona, 08916

    Enric Carcereny, Site 0006, 34934978925

    Recruiting

  • Hospital Universitari Dexeus

    Barcelona, Barcelona [Barcelona], 08028

    ANDRES AGUILAR, Site 0010, +34935460135

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], 08035

    Nuria Pardo Aranda, Site 0029, 0034932746085

    Recruiting

  • Hospital Universitario Reina Sofia

    Córdoba, 14004

    Maria Jose Ortiz Morales, Site 0027, 34635325317

    Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Comunidad de, 28034

    Pilar Garrido Lopez, Site 0024, (+34)913368263

    Recruiting

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007

    Antonio Calles Blanco, Site 0083, +34915868115

    Recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040

    Manuel Domine Gomez, Site 0015, 34915504800

    Recruiting

  • Hospital Universitario 12 De Octubre

    Madrid, 28041

    Maria Zurera Berjaga, Site 0062, 34976765746

    Recruiting

  • H.R.U Málaga - Hospital General

    Málaga, 29011

    María Vanesa Gutierrez Calderon, Site 0018, 34951308130

    Recruiting

  • Hospital Universitari Son Espases

    Palma, Balears [Baleares], 07120

    Aitor Azkarate, Site 0011, 0000000000

    Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008

    Miguel Fernández de Sanmamed Gutiérrez, Site 0009, 34948255400

    Recruiting

  • Hospital Universitario Virgen Macarena

    Seville, 41009

    David Vicente Baz, Site 0008, 34955008932

    Recruiting

  • Hospital Clinico de Valencia

    Valencia, Valenciana, Comunitat, 46010

    Valentina Gambardella, Site 0084, 34961973500

    Recruiting

Other trials in Spain

China13 sites

  • Local Institution - 0037

    Beijing, Beijing Municipality, 100142

    Withdrawn

  • Local Institution - 0038

    Changsha, Hunan, 410031

    Withdrawn

  • Local Institution - 0040

    Chengdu, Sichuan, 610041

    Withdrawn

  • Local Institution - 0044

    Hangzhou, Zhejiang, 310022

    Withdrawn

  • Local Institution - 0039

    Jinan, Shandong, 250117

    Withdrawn

  • Local Institution - 0047

    Linyi, Shandong, 276000

    Withdrawn

  • Local Institution - 0048

    Nanchang, Jiangxi, 330006

    Withdrawn

  • Local Institution - 0046

    Nanjing, Jiangsu, 210012

    Withdrawn

  • Local Institution - 0043

    Shanghai, Shanghai Municipality, 200032

    Withdrawn

  • Local Institution - 0049

    Shenyang, Liaoning, 110001

    Withdrawn

  • Local Institution - 0041

    Xi'an, 710061

    Withdrawn

  • Local Institution - 0045

    Xiamen, Fujian, 361003

    Withdrawn

  • Local Institution - 0042

    Zhengzhou, Henan, 450008

    Withdrawn

Other trials in China

Italy10 sites, 10 recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

    Bologna, 40138

    Francesco Gelsomino, Site 0053, +390512142203

    Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, 50134

    Lorenzo Antonuzzo, Site 0054, 00390557947298

    Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

    Meldola, Emilia-Romagna, 47014

    Angelo Delmonte, Site 0052, 390543739100

    Recruiting

  • Istituto Europeo di Oncologia IRCCS

    Milan, 20141

    Antonio Passaro, Site 0021, +390257489482

    Recruiting

  • Istituto Europeo di Oncologia IRCCS

    Milan, 20141

    Maria Zampino, Site 0107, 0257489258

    Recruiting

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, Piedmont, 10043

    Silvia Novello, Site 0020, 390119026322

    Recruiting

  • AO Santa Maria della Misericordia

    Perugia, Umbria, 06132

    Giulio Metro, Site 0026, 39755784185

    Recruiting

  • Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)

    Pesaro, Pesaro E Urbino, 61122

    Rita Chiari, Site 0079, +390755783688

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

    Roma, 00168

    Emilio Bria, Site 0031, +390458128124

    Recruiting

  • Istituto Nazionale Tumori Regina Elena

    Rome, Roma, 00144

    Federico Cappuzzo, Site 0019, +390586223189

    Recruiting

Other trials in Italy

Netherlands4 sites, 3 recruiting

  • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)

    Amsterdam, North Holland, 1066 CX

    Willemijn Theelen, Site 0034, 06-xxxxxxxx

    Recruiting

  • Local Institution - 0056

    Breda, North Brabant, 4818 CK

    Withdrawn

  • Ziekenhuis St. Jansdal

    Harderwijk, 3844 DG

    L.N. Boom, Site 0035, 0031341463504

    Recruiting

  • St. Antonius Ziekenhuis, locatie Utrecht

    Utrecht, 3543 AZ

    E. (Lisanne) Kastelijn, Site 0071

    Recruiting

Other trials in Netherlands

Greece3 sites, 3 recruiting

  • Alexandra General Hospital of Athens

    Athens, Attikí, 115 28

    Michalis Liontos, Site 0081, 306977009490

    Recruiting

  • Metropolitan Hospital

    Attiki, 18547

    Helena Linardou, Site 0022, 302104809852

    Recruiting

  • Theagenio Hospital

    Thessaloniki, Kentrikí Makedonía, 540 07

    THEODORA TSIOUDA, Site 0087, 00306932466411

    Recruiting

Other trials in Greece

Israel3 sites, 3 recruiting

  • Bnai Zion Medical Center

    Haifa, 31048

    Abed Agbarya, Site 0119, 9720543101186359359

    Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, 9103102

    Nir Peled, Site 0055, 97205870406206555727

    Recruiting

  • Tel Aviv Sourasky Medical Center - Oncology - Hematology/Oncology

    Tel Aviv, 6423906

    Ofer Merimsky, Site 0106, 97236974907

    Recruiting

Other trials in Israel

South Korea3 sites, 3 recruiting

  • National Cancer Center

    Goyang-si, Kyǒnggi-do, 10408

    Beung-Chul Ahn, Site 0069, 82222288133

    Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [Seoul], 03722

    Han Sang Kim, Site 0068, 82222241583

    Recruiting

  • Samsung Medical Center

    Seoul, 06351

    Se-Hoon Lee, Site 0070, 82-2-3410-1132

    Recruiting

Other trials in South Korea

United Kingdom3 sites, 3 recruiting

  • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital

    Birmingham, B9 5SS

    Shobhit Baijal, Site 0113, +44 121 627 5774

    Recruiting

  • Leicester Royal Infirmary-HOPE Clinical Trials Unit

    Leicester, LE1 5WW

    Samreen Ahmed, Site 0114, 0116 258 5998

    Recruiting

  • Guy's & St Thomas' NHS Foundation Trust

    London, London, City of, SE1 9RT

    Alexandros Georgiou, Site 0115, +44 20 7188 5368

    Recruiting

Other trials in United Kingdom

Brazil2 sites, 2 recruiting

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Clinical Oncology

    São Paulo, 01246000

    Camila Moniz, Site 0108, 55-11-99644-6112

    Recruiting

  • Fundacao Antonio Prudente - AC Camargo Cancer Center

    São Paulo, 01508-010

    Helano Freitas, Site 0111, 5511945544480

    Recruiting

Other trials in Brazil

Hungary2 sites, 2 recruiting

  • Orszagos Koranyi Pulmonologiai Intezet

    Budapest, 1121

    Gyula Ostoros, Site 0089, 3613913213

    Recruiting

  • Orszagos Onkologiai Intezet

    Budapest, 1122

    Tunde Nagy, Site 0067, 3612248600

    Recruiting

Other trials in Hungary

Australia1 site

  • Local Institution - 0093

    St Leonards, New South Wales, 2065

    Withdrawn

Other trials in Australia

Belgium1 site, 1 recruiting

  • AZ Maria Middelares

    Ghent, 9000

    Paul Germonpre, Site 0033, 3292468400

    Recruiting

Other trials in Belgium

Canada1 site, 1 recruiting

  • BC Cancer - Vancouver

    Vancouver, British Columbia, V5Z 4E6

    Janessa Laskin, Site 0072, 111-111-1111

    Recruiting

Other trials in Canada

Germany1 site, 1 recruiting

  • Klinikum Neuperlach

    München, 81737

    Stefan Boeck, Site 0012

    Recruiting

Other trials in Germany

Japan1 site, 1 recruiting

  • Ehime University Hospital

    Tōon, Ehime, 791-0295

    Shoichiro Yamamoto, Site 0110, +81-90-2789-2188

    Recruiting

Other trials in Japan

Poland1 site, 1 recruiting

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit

    Gdansk, 80-214

    Rafal Dziadziuszko, Site 0102, 48585844571

    Recruiting

Other trials in Poland

Portugal1 site, 1 recruiting

  • Instituto Português de Oncologia de Lisboa Francisco Gentil

    Lisbon, Lisbon District, 1099-023

    Telma Sequeira, Site 0014, 914000669

    Recruiting

Other trials in Portugal

Romania1 site

  • Local Institution - 0060

    Craiova, Dolj, 200746

    Withdrawn

Other trials in Romania

Singapore1 site, 1 recruiting

  • National Cancer Centre Singapore

    Singapore, 168583

    Qingqing Dawn Chong, Site 0088, 654368625

    Recruiting

Other trials in Singapore

About this study

Official title: Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Conditions
Solid Tumors
Being tested
Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel
Keywords
Adagrasib, KRAS G12C, KRAS, NSCLC, CRC, Krazati

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AdagrasibDrug

    Also called BMS-986503

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

  • CetuximabDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • DocetaxelDrug

    Specified dose on specified days

  • IrinotecanDrug

    Specified dose on specified days

  • LeucovorinDrug

    Also called Folinic acid

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

Study groups in NCT07415031
Study groupRoleWhat they receive
Arm A1ExperimentalNot described
Receives: Drug: Adagrasib
Arm A2ExperimentalNot described
Receives: Drug: Adagrasib
Arm B1ExperimentalNot described
Receives: Drug: Adagrasib; Drug: Pembrolizumab
Arm B2ExperimentalNot described
Receives: Drug: Adagrasib; Drug: Pembrolizumab
Arm B3ExperimentalNot described
Receives: Drug: Adagrasib; Drug: Cetuximab
Arm B4ExperimentalNot described
Receives: Drug: Adagrasib; Drug: Pembrolizumab; Drug: Pemetrexed
Arm C1ExperimentalNot described
Receives: Drug: Pembrolizumab
Arm C2ExperimentalNot described
Receives: Drug: Docetaxel
Arm C3ExperimentalNot described
Receives: Drug: Irinotecan; Drug: Leucovorin; Drug: Fluorouracil
Arm C4ExperimentalNot described
Receives: Drug: Leucovorin; Drug: Oxaliplatin; Drug: Fluorouracil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Adverse Events (AEs)

    Measured: Up to 90 days from last dose or study discontinuation

  2. Number of Participants With AEs Leading to Treatment Discontinuation

    Measured: Up to 90 days from last dose or study discontinuation

  3. Number of Participants With Serious Adverse Events (SAEs)

    Measured: Up to 90 days from last dose or study discontinuation

  4. Number of Participants With AEs Leading to Death

    Measured: Up to 90 days from last dose or study discontinuation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2026
  2. Study start6 May 2026
  3. Primary completion16 Feb 2028 (estimated)
  4. Study completion16 Feb 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
170 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07415031
Sponsor's protocol ID
CA239-0071
Other IDs
EU CTR, WHO
Status last verified
Oct 2026
First submitted
11 Feb 2026
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Adagrasib, Pembrolizumab and Cetuximab in people with Solid Tumors, run by Mirati Therapeutics Inc. at 101 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 101 sites in France, United States, Spain, China, Italy and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact BMS Clinical Trials Contact Center www.BMSClinicalTrials.com (855-907-3286, Clinical.Trials@bms.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Adverse Events (AEs) (time frame: Up to 90 days from last dose or study discontinuation). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07415031.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in